Intellia Therapeutics’ (NTLA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

Several other equities research analysts have also recently issued reports on NTLA. New Street Research set a $25.00 price objective on Intellia Therapeutics in a report on Monday, June 15th. Wolfe Research cut Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Wedbush lifted their price target on Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, July 10th. Finally, Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target on the stock in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus target price of $20.98.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.74 on Wednesday. The firm has a fifty day moving average of $12.45 and a 200 day moving average of $13.40. The firm has a market cap of $1.65 billion, a PE ratio of -3.49 and a beta of 1.82. Intellia Therapeutics has a one year low of $7.95 and a one year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). The business had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s revenue was down 46.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share. On average, equities analysts predict that Intellia Therapeutics will post -3.21 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP J III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Michael Dube sold 2,641 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Comerica Bank lifted its stake in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $30,000. Freestone Grove Partners LP purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at about $33,000. Finally, Nykredit A S purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.